Literature DB >> 18302157

Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography.

Chun-Ru Chien1, Tony Hsiu-Hsi Chen.   

Abstract

This study aimed to estimate the mean sojourn time (MST) and sensitivity of asymptomatic lung cancer (ALC) detected by computed tomography (CT) or chest X-ray (CXR). Translation of early diagnosis into mortality reduction by 2 detection modalities and inter-screening interval was projected using a Markov model. On the basis of systematic literature review, data from 6 prospective CT screening studies were retrieved. The MST in association with the natural history of lung cancer depicted by a 3-state Markov model was estimated with a Bayesian approach. To project mortality reduction attributed to screening, the model was further extended to 5 health states for the inclusion of prognostic part. The analysis was run with a 10-year time horizon of follow-up, mimicking the Dutch-Belgian randomized lung cancer screening trial (NELSON). Screening for lung cancer with CT had high sensitivity (median: 97%) and may advance 1 year earlier than CXR in detecting ALC. By simulating the scenario similar to NELSON study, CT screen may gain an extra of 0.019 year of life expectancy per person, yields 15% mortality reduction (relative risk (RR): 0.85, 95% confidence interval [95%CI: (0.58-1.01)]. Approximate 23% [RR: 0.77, 95%CI: (0.43-0.98)] mortality reduction would be achieved by annual CT screening program. The mortality findings in conjunction with higher sensitivity and shorter MST estimate given data on prevalent and incident (2nd) screen may provide a tentative evidence, suggesting that annual CT screening may be required in order to be effective in reducing mortality before the results of randomized controlled studies available. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18302157     DOI: 10.1002/ijc.23413

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Sojourn time and lead time projection in lung cancer screening.

Authors:  Dongfeng Wu; Diane Erwin; Gary L Rosner
Journal:  Lung Cancer       Date:  2010-11-13       Impact factor: 5.705

2.  Short- and long-term lung cancer risk associated with noncalcified nodules observed on low-dose CT.

Authors:  Paul F Pinsky; P Hrudaya Nath; David S Gierada; Sushil Sonavane; Eva Szabo
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-22

3.  A different interpretation of the efficacy of lung cancer screening in the PLCO trial.

Authors:  Motoyasu Sagawa; Tomio Nakayama; Tomotaka Sobue
Journal:  Eur J Epidemiol       Date:  2015-07-22       Impact factor: 8.082

4.  Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials.

Authors:  Kevin Ten Haaf; Joost van Rosmalen; Harry J de Koning
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-13       Impact factor: 4.254

5.  Modeling the mortality reduction due to computed tomography screening for lung cancer.

Authors:  Millennia Foy; Rowena Yip; Xing Chen; Marek Kimmel; Olga Y Gorlova; Claudia I Henschke
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

6.  Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.

Authors:  Ayush Sharma; Thomas C Smyrk; Michael J Levy; Mark A Topazian; Suresh T Chari
Journal:  Gastroenterology       Date:  2018-04-30       Impact factor: 22.682

7.  Modeling progression in radiation-induced lung adenocarcinomas.

Authors:  Hatim Fakir; Werner Hofmann; Rainer K Sachs
Journal:  Radiat Environ Biophys       Date:  2010-01-08       Impact factor: 1.925

8.  Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period.

Authors:  Pamela M McMahon; Chung Yin Kong; Milton C Weinstein; Angela C Tramontano; Lauren E Cipriano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

9.  Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening.

Authors:  A W Castleberry; D Smith; C Anderson; A J Rotter; F W Grannis
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

Review 10.  Lung cancer screening update.

Authors:  Massimo Bellomi; Cristiano Rampinelli; Elvio De Fiori; Lorenzo Preda; Giulia Veronesi
Journal:  Cancer Imaging       Date:  2009-10-02       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.